Navigation Links
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

eive infusions of REMICADE 5 mg/kg at weeks 0, 2 and 6 and every six weeks thereafter through week 96 (n = 201) or placebo (n = 78). The primary endpoint of the trial was a 20 percent decrease in disease activity score on the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) at week 24.

At week 24, placebo patients were crossed over to receive treatment with REMICADE 5 mg/kg at weeks 0, 2 and 6 and every six weeks thereafter and continued on REMICADE through the remainder of the study (96 weeks). Starting at week 36, and continuing through week 96, patients initially randomized to receive REMICADE 5 mg/kg had their dose increased to 7.5 mg/kg if they had a BASDAI of at least 3 in two consecutive evaluations to assess the potential for improved response through increased dosing. Using these rather strict criteria, 106 patients (53 percent) received a dose increase some time after week 30.

Nine percent of patients who received REMICADE through week 102 discontinued the study due to adverse events (AEs). During the study, REMICADE was generally well-tolerated. At week 24, the most commonly reported AEs were upper respiratory tract infections, which occurred at a rate of 15 percent in the placebo group, compared with 14 percent in the REMICADE group. The only laboratory abnormalities that occurred more frequently with REMICADE compared with placebo were asymptomatic liver enzyme test elevations. At week 24, serious (AEs) were reported in 4 percent of REMICADE-treated patients, compared with three percent of patients receiving placebo. AEs were generally mild and were consistent with REMICADE prescribing information.

There were no reports of congestive heart failure, tuberculosis or serious infections in the study population. Three malignancies were reported in three patients during the ASSERT study and included squamous cell skin cancer, lung cancer and breast cancer. Please see "Important Safety Information" below.

About Ankyl
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
Post Your Comments:
(Date:12/16/2009)... Verathon®, maker of BladderScan® bladder volume instruments ... volume ultrasound is now included in the ... of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... November 2009, replace the previous guidelines which ... are located on the Web at: ...
(Date:12/16/2009)... CHARLOTTESVILLE, Virginia, December 16 Biovista Inc.,today ... Innovator Presentation Award,in Healthcare, at the 2009 New ... MA. The award, which recognizes cutting edge private ... Biovista who competed with,over 50 other privately held ... the Technology, Life Sciences and Clean-tech sectors. , ...
(Date:12/16/2009)... CVS/pharmacy and MinuteClinic health care centers ... H1N1 vaccine in 20 states and Washington, D.C. ... receiving H1N1 vaccines continue, many states have lifted ... receive the shot while supplies last. In ... is available at MinuteClinic locations across the country ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Biovista Inc. Named Top Innovator in Life Sciences 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4SRI Internationals Research on Nicotine Use and Dependence Featured in the National Cancer Institutes Tobacco Control Monograph Series 56811 1SRI Internationals Research on Nicotine Use and Dependence Featured in the National Cancer Institutes Tobacco Control Monograph Series 56811 2SRI Internationals Research on Nicotine Use and Dependence Featured in the National Cancer Institutes Tobacco Control Monograph Series 56811 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network 28PHIN 29 Con 13987 1Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network 28PHIN 29 Con 13987 2Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network 28PHIN 29 Con 13987 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network 28PHIN 29 Con 13987 4Research Seeks Cause of Preeclampsia 56807 1Research Seeks Cause of Preeclampsia 56807 2
... April 1, 2008 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... as the Principal Investigator for its Phase II,clinical ... Dr. Dib is currently the Director of ... Center and Mercy,Gilbert Medical Center in Arizona, as ...
... Center for,Translational Molecular Medicine (CTMM) - a Dutch ... new techniques for,the diagnosis and treatment of major ... research funding amounting to a total of 150 ... of small and,medium-sized enterprises, major industry leaders including ...
Other Medicine Technology:CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial 2CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial 3Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease 2
(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...
(Date:12/16/2009)... for use, expert says, , , WEDNESDAY, Dec. 16 (HealthDay ... less likely to die when they receive an implantable ... included 4,685 people, ages 65 to 85, who were ... fraction (a measure of the heart,s pumping ability) of ... those who were treated with standard medication and an ...
(Date:12/16/2009)... -- Medical travel facilitator Companion Global Healthcare Inc. ... into its network of international hospitals that treat ... at mainland U.S. facilities. ,, The announcement means ... and preferred pricing for its individual clients and ... HIMA San Pablo Bayamon or HIMA San Pablo ...
(Date:12/16/2009)... -- Quantros, Inc., a leading provider of safety ... the healthcare industry, announces the creation of a ... software industry veteran Michael Tulloch, MBA, as Director ... the company,s new Marlborough, MA office. ,, "The ... explains Tulloch. "Quantros has been developing software for ...
(Date:12/16/2009)... families of sick and dying hospitalized children ask their ... do pediatricians respond to such personal requests? While increasing ... some patients and families cope with serious illness, a ... families and patients who raise the issue of prayer, ... of Southern Medical Journal , Brandeis and Rice ...
Breaking Medicine News(10 mins):Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Implanted Defibrillator Might Extend Life 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2
... COM, VANCOUVER, Nov. 20 /PRNewswire-FirstCall/ - ... initiation of subject dosing in its,Phase 1 ... will measure the safety, tolerability, pharmacokinetics,and pharmacodynamics ... each subject,receiving a 15-minute loading dose at ...
... Kay Jewelers returns to national campaign for fourth year to ... lives in communities everywhere., AKRON, Ohio, Nov. 20 ... kicks off its annual Thanks and Giving,campaign. This is the ... Jewelers has partnered with St. Jude in fundraising campaigns. ...
... to Help People ... and Get in Better Shape, BEVERLY HILLS, Calif., Nov. 20 ... Dollar Body Game(TM), an ongoing incentive competition that is,giving away over ... shape. Dottie Buck of Shreveport, La., just won $10,000 for ...
... all help spot a variety of underlying disorders , ... and MRI or CT brain scans should be considered ... unprovoked seizure, according to a new guideline released by ... this approach can often detect brain abnormalities that caused ...
... Friendship All Natural Cottage Cheese and NBC 10 Announce Winner of ... ... Eight weeks and 23 pounds later,Edgewater Park, New Jersey resident Keisha ... Friendship All Natural,Cottage Cheese Local Loser Contest." In a mere eight ...
... of National Health ... WASHINGTON, Nov. 20 Internet2 applauds the Federal,Communications ... recipients of its new Rural Health Care Pilot Program,which ... healthcare,network that will serve the national interest by improving ...
Other Medicine News:Health News:Cardiome Initiates Phase 1 Study for GED-aPC 2Health News:Cardiome Initiates Phase 1 Study for GED-aPC 3Health News:Cardiome Initiates Phase 1 Study for GED-aPC 4Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 2Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 3Health News:Shreveport, LA Mother Wins $10,000 for Losing 50 Pounds 2Health News:Shreveport, LA Mother Wins $10,000 for Losing 50 Pounds 3Health News:Experts Issue Guidelines on Diagnosing Seizure 2Health News:Keisha Orr of Edgewater Park, New Jersey is Named Philadelphia's 2007 'Local Loser' 2Health News:Internet2 Congratulates FCC Rural Health Care Pilot Program Grant Awardees 2Health News:Internet2 Congratulates FCC Rural Health Care Pilot Program Grant Awardees 3
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
The Clinac 6EX accelerator is a cost-effective choice. Configured for the latest treatment techniques, the Clinac 6EX has the tightest mechanical and dosimetric specifications for any single-energy m...
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Medicine Products: